Myelodysplastic Syndromes

>

Latest News

The guideline update follows the FDA’s approval of imetelstat in patients with lower-risk MDS based on data from the phase 3 IMerge trial.
Updated NCCN Guidelines Recommend Imetelstat for Anemia in Lower-Risk MDS

July 31st 2024

The guideline update follows the FDA’s approval of imetelstat in patients with lower-risk MDS based on data from the phase 3 IMerge trial.

Safety Profile of Oral Azacitadine Remains Consistent in Lower-Risk MDS
Safety Profile of Oral Azacitadine Remains Consistent in Lower-Risk MDS

June 2nd 2024

Data from the phase 3 COMMANDS trial support the expanded European approval of frontline luspatercept for transfusion-dependent anemia in lower-risk myelodysplastic syndromes.
Luspatercept Earns Expanded European Approval for Anemia in Lower-Risk MDS

April 3rd 2024

Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.
FDA ODAC Votes in Favor of Imetelstat Benefits Vs Risks in Lower-Risk MDS

March 14th 2024

Treatment with rusfertide may reduce the use of phlebotomy and limit debilitating disease-related symptoms in patients with polycythemia vera based on findings from the phase 2 REVIVE trial.
Rusfertide May Help Control Erythrocytosis in Polycythemia Vera

March 8th 2024

<12345